Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in its own shares conducted on 14 July 2025. The report covers a single day of trading activity executed through the corporate stockbroker, Merrill Lynch International, pursuant to a non-discretionary agreement entered into on 4 June 2025.
Key Financial Metrics
The filing details a share repurchase program with the following metrics for the reporting date:
- Shares Purchased (Daily): 482,889 ordinary shares.
- Price Range (GBp): Lowest 1,405.50p; Highest 1,426.00p.
- Volume-Weighted Average Price (GBp): 1,417.58p.
- Trading Venue: London Stock Exchange (XLON).
- Treasury Shares Held (Post-Transaction): 230,857,169 shares.
- Shares in Issue (Excluding Treasury): 4,084,526,888 shares.
- Treasury Voting Rights Percentage: 5.65%.
The filing does not provide data on revenue, profit, cash flow, margins, or debt levels.
Material Changes
Since the commencement of the current buyback agreement on 4 June 2025, the Company has purchased a total of 12,722,786 ordinary shares. The transaction reported on 14 July 2025 represents a continuation of this program, increasing the total treasury holding to approximately 230.9 million shares.
Outlook and Management Commentary
The purchased shares are held as Treasury shares. The filing confirms compliance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules (DTR 5.5.1R). There is no forward-looking guidance, management commentary on operational performance, or discussion of risks and contingencies in this specific filing.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback program since 4 June 2025 (12,722,786).
- Confirm the updated total of treasury shares held (230,857,169) and the resulting voting rights percentage (5.65%).
- Check the volume-weighted average price paid (1,417.58p) against market closing prices for 14 July 2025.
- Review the non-discretionary agreement terms announced on 4 June 2025 to understand the remaining authorization for the buyback program.